|
|
|
| 阿帕他胺治疗高龄转移性激素敏感性前列腺癌2例报道并文献复习 |
| 陈亮, 吴天鹏*, 宋超, 刘凌琪, 禹刚 |
| 武汉大学人民医院泌尿外科,武汉 430060 |
|
| Efficacy of apalutamide in the treatment of elderly metastatic hormone sensitive prostate cancer：two cases report and literature review |
| Chen Liang, Wu Tianpeng*, Song Chao, liu linqi, Yu Gang |
| Department of Urology, Renming Hospital of Wuhan University, Hubei Province, Wuhan 430060, China |
| 引用本文: |
陈亮, 吴天鹏, 宋超, 刘凌琪, 禹刚. 阿帕他胺治疗高龄转移性激素敏感性前列腺癌2例报道并文献复习[J]. 微创泌尿外科杂志, 2022, 11(2): 123-127.
Chen Liang, Wu Tianpeng, Song Chao, liu linqi, Yu Gang. Efficacy of apalutamide in the treatment of elderly metastatic hormone sensitive prostate cancer：two cases report and literature review. JOURNAL OF MINIMALLY INVASIVE UROLOGY, 2022, 11(2): 123-127.
|
|
|
|
| 链接本文: |
| http://journal20.magtechjournal.com/Jwk_zgmnwk/CN/abstract/abstract1759.shtml 或 http://journal20.magtechjournal.com/Jwk_zgmnwk/CN/Y2022/V11/I2/123 |
[1] BRAY F, FERLAY J, SOERJOMATARAM I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.
[2] 孙颖浩.粱朝朝,高旭,等.中国泌尿外科疾病诊断治疗指南(2019版)[M].北京:科学出版社,2020: 85-123.
[3] VIRANI S S, ALONSO A, BENJAMIN E J, et al.Heart disease and stroke statistics-2020 update: a report from the American heart association[J]. Circulation,2020,141(9):e139-e596.
[4] ZHANG KW, REIMERS MA, CALAWAY AC, et al.Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS)[J]. J Urol,2022,207(1):242-243.
[5] SMITH MR, SAAD F, CHOWDHURY S, et al.Apalutamide treatment and metastasis-free survival in prostate cancer[J]. N Engl J Med,2018,378(15):1408-1418.
[6] CORNFORD P, BELLMUNT J, BOLLA M, et al.EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer[J]. Eur Urol,2017,71(4):630-642.
[7] FRIEDLANDER TW, RYAN CJ.Targeting the androgen receptor[J]. Urol Clin North Am,2012,39(4):453-464.
[8] RYAN C J, SMITH M R, FIZAZI K, et al.Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study[J]. Lancet Oncol,2015,16(2):152-160.
[9] FIZAZI K, SCHER H I, MOLINA A, et al.Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study[J]. Lancet Oncol,2012,13(10):983-992.
[10] CLEGG NJ, WONGVIPAT J, JOSEPH JD, et al.ARN-509: a novel antiandrogen for prostate cancer treatment[J]. Cancer Res,2012,72(6):1494-1503.
[11] SMITH M R, SAAD F, CHOWDHURY S, et al.Apalutamide and overall survival in prostate cancer[J]. Eur Urol,2021,79(1):150-158.
[12] CHI K N, CHOWDHURY S, BJARTELL A, et al.Apalutamide in patients with metastatic Castration-Sensitive prostate cancer: final survival analysis of the randomized, Double-Blind, phase III TITAN study[J]. J Clin Oncol,2021,39(20):2294-2303.
[13] WENZEL M, NOCERA L, COLLA RC, et al. Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis[J]. 2021 May 30. doi: 10.1038/s41391-021-00395-4.Online ahead of print.
[14] TOHI Y, KATAOKA K, MIYAI Y, et al.Apalutamide-associated skin rash in patients with prostate cancer: Histological evaluation by skin biopsy[J]. IJU Case Rep,2021,4(5):299-302.
[15] OUDARD S, HADASCHIK B, SAAD F, et al.Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation Therapy[J].Eur Urol Focus,2021,(21):S2405-S4569.
[16] MOHLER J L, ANTONARAKIS E S, ARMSTRONG A J, et al.Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw,2019,17(5):479-505.
[17] NELSON P S.Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer[J]. J Clin Oncol,2012,30(6):644-646.
[18] RYDZEWSKA L, BURDETT S, VALE C L, et al.Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis[J]. Eur J Cancer,2017,84: 88-101.
[19] SAKAMOTO S.Editorial comment to apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: a subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study[J]. Int J Urol,2021,28(3):288.
[20] CHUNG B H, HUANG J, Ye ZQ, et al.Apalutamide for patients with metastatic castrationsensitive prostate cancer in East Asia:a subgroup analysis of the TITAN trial[J]. Asian J Androl,2022;24(2):161-166.
[21] SATO H, NARITA S, TSUCHIYA N, et al.Impact of early changes in serum biomarkers following androgen deprivation therapy on clinical outcomes in metastatic hormone-sensitive prostate cancer[J]. BMC Urol,2018,18(1):32.
[22] TOMIOKA A, TANAKA N, YOSHIKAWA M, et al.Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer[J]. BMC Urol,2014,14:33. |
| [1] |
杜仁继, 缪惠东. 雄激素剥夺联合阿帕他胺治疗转移性激素敏感性前列腺癌2例报道[J]. 微创泌尿外科杂志, 2022, 11(2): 117-119. |
| [2] |
卢凯, 陈恕求, 吴剑平, 许斌, 陈明. 以血小板减少为首发症状的前列腺癌骨髓转移1例报道[J]. 微创泌尿外科杂志, 2022, 11(2): 131-133. |
| [3] |
张一鸣, 许鹏, 温勇, 邹杰鹏, 刘春晓, 陈玢屾. 阿帕他胺新型内分泌治疗结合手术实现局限性高危前列腺癌病理完全缓解1例报道[J]. 微创泌尿外科杂志, 2022, 11(2): 120-122. |
| [4] |
董滢, 卜小斌, 许平, 黄治鑫. 两种方法治疗高龄、高危BPH合并膀胱多发结石的疗效比较[J]. 微创泌尿外科杂志, 2018, 7(4): 254-257. |
| [5] |
李碧锦, 李军, 凌凯南, 季志强. 双极等离子切除术治疗高龄高危膀胱肿瘤复发情况及其与癌组织VEGF、Survivin表达水平的关系[J]. 微创泌尿外科杂志, 2017, 6(4): 230-234. |
| [6] |
黄辉虎, 狄金明, 郭晓峰, 王仕钦, 彭玉平, 王之仕. 前列腺切除术后并发症在高龄高危患者中的预防与治疗[J]. 微创泌尿外科杂志, 2017, 6(3): 162-164. |
| [7] |
王建龙, 朱刚, 金滨, 刘明, 王建业, 万奔. 高龄前列腺增生患者行2 μm激光前列腺切除术临床疗效及安全性分析[J]. 微创泌尿外科杂志, 2013, 2(4): 271-273. |
| [8] |
李建明, 李小鑫, 王伟, 解吕中. 选择性绿激光前列腺汽化术治疗高龄前列腺增生的疗效观察(附33例报告)[J]. 微创泌尿外科杂志, 2013, 2(4): 274-276. |
|
|
|
|
